Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$38.96 - $42.75 $8.24 Million - $9.04 Million
211,440 Added 10.9%
2,151,641 $88 Million
Q1 2024

May 15, 2024

BUY
$40.88 - $43.27 $79.3 Million - $84 Million
1,940,201 New
1,940,201 $82 Million

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track George Soros's Portfolio

Track George Soros Portfolio

Follow George Soros (Soros Fund Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Soros Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Soros Fund Management LLC and George Soros with notifications on news.